Oral cephalosporin antibiotics: An overview of clinical pharmacology and dermatologic applications

Cutis

Volumn 71, Issue 2, 2003, Pages 153-157

  Del Rosso, James Q ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}  

^a UNIVERSITY OF NEVADA   (United States)

^b 3M COMPANY   (United States)

^c ALLERGAN INC   (United States)

^d Berlex Laboratories   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f Bradley Pharmaceuticals Inc   (United States)

^g Dermik Laboratories Inc   (United States)

^h Galderma Laboratories   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j Healthpoint Ltd   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^l Dermatology Company   (France)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ Ortho Neutrogena   (United States)

^o Las Vegas Skin & Cancer Clinics Ltd   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; CARBACEPHEM DERIVATIVE; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFDINIR; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFRADINE; CEFTIBUTEN; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; FERROUS SULFATE; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON SALT; KEFTAB; LORACARBEF; WARFARIN; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; BREAST FEEDING; CROSS REACTION; DERMATOLOGY; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; EOSINOPHILIA; FEVER; GASTROINTESTINAL SYMPTOM; GESTATION PERIOD; GLOMERULONEPHRITIS; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY; HYPOCOMPLEMENTEMIA; LIVER TOXICITY; LYMPHADENOPATHY; NEPHROTOXICITY; PAPULAR SKIN DISEASE; PHARMACOLOGY; PSEUDOMEMBRANOUS COLITIS; RASH; REVIEW; RISK FACTOR; SERUM SICKNESS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; URTICARIA; VASCULITIS; CHEMICALLY INDUCED DISORDER; DRUG HYPERSENSITIVITY; ORAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DERMATOLOGIC AGENTS; DRUG HYPERSENSITIVITY; HUMANS; SKIN DISEASES, INFECTIOUS; UNITED STATES;

EID: 0038481633     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Bo G. Giuseppe Brotzu and the discovery of cephalosporins. Clin Microbiol Infect. 2000;6(suppl 3):6-9.
2. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill-Livingstone; 2000:274-291.
3. Moellering RC, Sentochnik DE. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. 2nd ed. Philadelphia, Pa: WB Saunders; 1998:185-197.
4. Sadick NS. Systemic antibiotic agents. Dermatol Clin. 2001;19:1-21.
5. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc. 1999;74:187-195.
6. Neu HC. The new beta-lactamase stable cephalosporins. Ann Intern Med. 1982;97:408-419.
7. Mandell GL, Petri WA. Antimicrobial agents: penicillins, cephalosporins and other beta-lactam antibiotics. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1073-1101.
8. Montiel NJ, Baumgarten JM, Sinha AA. Lyme disease - part II: clinical features and treatment. Cutis. 2002;69:443-448.
9. Del Rosso JQ. Cephalosporin antibiotics. Clin Dermatol. In press.
10. Fung-Tomc JC, Huczko E, Stickle T, et al. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother. 1995;39:533-538.
11. Labia R, Morand A. Interaction of cefdinir with betalactamases. Drugs Exp Clin Res. 1994;20:43-48.
12. Craig WA. Pharmacokinetics of antibiotics with special emphasis on cephalosporins. Clin Microbiol Infect. 2000;6(suppl 3):46-49.
13. Mazzei T, Dentico P. The pharmacokinetics of oral cephalosporins. Clin Microbiol Infect. 2000;6(suppl 3):53-54.
14. Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet. 1995;28:361-384.
15. Craft JC, Parish LC. Systemic antimicrobial therapy. In: Millikan LE, ed. Drug Therapy in Dermatology. New York, NY: Marcel Dekker; 2000:57-78.
16. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89-96.
17. Lipsky BA, Berendt AR. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev. 2000;16:S42-S46.
18. Sadick NS. Current aspects of bacterial infections of the skin. Dermatol Clin. 1997;15:341-349.
19. El-Tahawy AT. Bacteriology of diabetic foot infections. Saudi Med J. 2000;21:344-347.
20. Sultan T, Baltch AL, Smith RP, et al. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients. Chemotherapy. 1994;40:80-91.
21. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992;117:273-280.
22. Page J, Levinson ME, Thornhill TS, et al. Treatment of soft tissue infection with cephalexin. JAMA. 1970;211:1837-1839.
23. Mallory SB. Azithromycin compared to cephalexin in the treatment of skin and skin structure infections. Am J Med. 1991;91:36S-39S.
24. Lipsky BA, Yarbrough DR III, Walker FB, et al. Ofioxacin versus cephalexin for treating skin and soft tissue infections. Int J Dermatol. 1992;31:443-445.
25. Kefiex (cephalexin) [US product monograph]. Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics; 2001:1124-1125.
26. Madaras-Kelly KJ, Arbogast R, Jue S. Increased therapeutic failure for cephalexin versus comparator antibiotics. Pharmacotherapy. 2000;20:199-205.
27. Tack KJ, Littlejohn TW, Mailloux G, et al. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. Clin Ther. 1998;20:244-256.
28. Tack KJ, Keyserling CH, McCarty J, et al. Study of the use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. Antimicrob Agents Chemother. 1997;41:739-742.
29. Klein JO, McCracken GH. Summary: role of a new oral cephalosporin, cefdinir, for therapy of infections of infants and children. Pediatr Infect Dis. 2000;19:S181-S183.
30. Mine Y, Kamimura T, Watanabe Y, et al. In vitro antibacterial activity of FK482, a new orally active cephalosporin. J Antibiot (Tokyo). 1988;41:1873-1887.
31. Cohen MA, Joannides ET, Roland GE, et al. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability. Diagn Microbiol Infect Dis. 1994;18:31-39.
32. Guay DRP. Cefdinir: an expanded-spectrum oral cephalosporin. Ann Pharmacother. 2000;34:1469-1477.
33. Wiseman LR, Benfield P. Cefprozil: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs. 1993;45:295-317.
34. Nolen T, Conetta BJ, Durham SJ, et al. Safety and efficacy of cefprozil vs cefaclor in the treatment of mild to moderate skin and skin-structure infections. Infect Med. 1992;9:S66-S68.
35. Parish LC, Doyle CA, Durham SJ, et al. Cefprozil vs cefaclor in the treatment of mild to moderate skin and skin-structure infections. Clin Ther. 1992;14:453-469.
36. Wachs G, Rogan MP. Cefprozil vs erythromycin for mild to moderate skin and skin-structure infections. Infect Med. 1992;9:S57-S65.
37. Solomon E, McCarty JM, Morman MR, et al. Comparison of cefprozil and amoxicillin/clavulanate potassium in the treatment of skin and skin-structure infections in adults. Adv Ther. 1992;9:156-165.
38. Anne S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol. 1995;74:167-170.
39. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Baltimore, Md: Williams & Wilkins; 1998:151-170.
40. Omnicef (cefdinir) [US product monograph]. Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics; 2001:478-483.
41. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 1994;93:137-150.
42. Knowkes SR, Shear NH. Drug hypersensitivity syndromes. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, Pa: WB Saunders; 2001:876-877.
43. Heckbert S, Stryker W, Coltin K, et al. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol. 1990;132:336-342.
44. Stockley IH. Drug Interactions. Nottingham, England: Pharmaceutical Press; 1999.
45. Tatro DS. Drug Interaction Facts. St. Louis, Mo: Facts & Comparisons Division, JB Lippincott; 2001.
46. Ueno K, Tanaka K, Tsujimura K, et al. Impairment of cefdinir absorption by iron ion. Clin Pharmacol Ther. 1993;54:473-475.